New biologic agents for the treatment of gynecologic cancers

Hematology/Oncology Clinics of North America

Volumn 26, Issue 1, 2012, Pages 133-156

  Horowitz, Neil ^a   Matulonis, Ursula A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenesis inhibitors; Cervical cancer; Endometrial cancer; Ovarian cancer; Phosphoinositide 3 kinase inhibitors; Poly ADP ribose polymerase inhibitors

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMN 673; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CEP 9722; CISPLATIN; DOCETAXEL; E 7016; ENMD 2076; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; RF 01367338; RUCAPARIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VISMODEGIB;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APLASTIC ANEMIA; BLEEDING; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DNA REPAIR; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ENDOMETRIUM CANCER; FATIGUE; GASTROINTESTINAL DISEASE; GRANULOCYTE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MAINTENANCE THERAPY; METABOLIC DISORDER; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM; VOMITING; VULVA CANCER; WART VIRUS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; GENITAL NEOPLASMS, FEMALE; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84855908079     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.11.002     Document Type: Review

References (99)

1. Martin L., Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. JClin Oncol 2007, 25:2894-2901.
2. Zhang L., Yang N., Garcia J.R., et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002, 161:2295-2309.
3. Cooper B.C., Ritchie J.M., Broghammer C.L., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002, 8:3193-3197.
4. Hefler L.A., Zeillinger R., Grimm C., et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006, 103:512-517.
5. Burger R.A., Sill M.W., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. JClin Oncol 2007, 25:5165-5171.
6. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. JClin Oncol 2007, 5:5180-5186.
7. Randall L.M., Monk B.J. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010, 117:497-504.
8. Tew WP, Colombo N, Ray-Coquard I, etal. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized, multicenter phase II study [abstract 5508]. In: Proceedings of the 2007 American Society of Clinical Oncology meeting.
9. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. JClin Oncol 2009, 27:5601-5606.
10. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group Trial. J Clin Oncol 2011, 29:69-75.
11. Biagi J.J., Oza A.M., Chalchal H.I., et al. Aphase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 2011, 22:335-340.
12. Friedlander M., Hancock K.C., Rischin D., et al. Aphase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37.
13. Matulonis U, Tew WP, Matei D, etal. A phase II study of ENMD2076 in platinum-resistant ovarian cancer [abstract 5021]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting.
14. Vergote I, Sella A, Bedell C, etal. Phase II study of XL184 in a cohort of ovarian cancer patients with measurable soft tissue disease [abstract 407]. Proceedings of the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics conference. 2010.
15. Ledermann J.A., Hackshaw A., Kaye S., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. JClin Oncol 2011, 29:3798-3804.
16. Matulonis U.A. Bevacizumab and its use in epithelial ovarian cancer. Future Oncol 2011, 7:365-379.
17. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011, 121:230-238.
18. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. JClin Oncol 2008, 26:76-82.
19. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. JClin Oncol 2010, 28:154-159.
20. Rose PG, Drake R, Braly PS, etal. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube [abstract 5546]. In: Proceedings of the 2009 American Society of Clinical Oncology meeting.
21. Tillmanns TD, Lowe MP, Schwartzberg LS, etal. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma [abstract 5009]. In: Proceedings of the 2010 American Society of Clinical Oncology meeting.
22. Raja F.A., Griffin C.L., Qian W., et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011, 105:884-889.
23. Coleman R.L., Duska L.R., Ramirez P.T., et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011, 12(12):1109-1117.
24. Karlan BY, Oza AM, Hansen VL, etal. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma [abstract 5000]. In: Proceedings of the 2010 American Society of Clinical Oncology meeting.
25. NCT00390611. Paclitaxel and carboplatin with or without sorafenib in the first-line treatment of patients with ovarian cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00390611.
26. Burger RA, Brady MF, Bookman MA, etal. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract LBA1]. In: Proceedings of the 2010 American Society of Clinical Oncology meeting.
27. Perren T, Swart AM, Pfisterer J, etal. ICON7: a phase III randomised Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer [abstract LBA4]. In: Proceedings of the 2010 European Society of Medical Oncology meeting.
28. Kristensen GB, Perren T, Qian W, etal. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract LBA 5006]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting.
29. NCT01015118. BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT01015118.
30. NCT00866697. Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00866697.
31. NCT00951496. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00951496.
32. NCT01167712. Paclitaxel and carboplatin with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT01167712.
33. Aghajanian C, Finkler NJ, Rutherford T, etal. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer [abstract LBA 5007]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting.
34. NCT00565851. Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00565851.
35. NCT00544973. An RCT of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer (ICON6). Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00544973.
36. NCT01204749. TRINOVA-1: a study of AMG386 or placebo, in combination with weekly paclitaxel chemotherapy, as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT01204749.
37. Kamat A.A., Merritt W.M., Coffey D., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007, 13:7487-7495.
38. Aghajanian C., Sill M.W., Darcy K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. JClin Oncol 2011, 29:2259-2265.
39. Correa R, Mackay H, Hirte HW, etal. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia [abstract 5038]. In: Proceedings of the 2010 American Society of Clinical Oncology meeting.
40. Nimeiri H.S., Oza A.M., Morgan R.J., et al. Aphase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010, 117:37-40.
41. McMeekin D.S., Sill M.W., Benbrook D., et al. Aphase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 105:508-516.
42. Cheng W.F., Chen C.A., Lee C.N., et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000, 96:721-726.
43. Cooper R., Logue J., Davidson S., et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000, 83:620-625.
44. Guidi A.J., Abu-Jawdeh G., Berse B., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. JNatl Cancer Inst 1995, 87:1237-1245.
45. Toussaint-Smith E., Donner D.B., Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004, 23:2988-2995.
46. López-Ocejo O., Viloria-Petit A., Bequet-Romero M., et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000, 19:4611-4620.
47. Monk B.J., Sill M.W., Burger R.A., et al. Phase II study of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group. JClin Oncol 2009, 27:1069-1074.
48. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab intreating patients with stage IVB, recurrent, or persistent cervical cancer. Available at: Accessed November 15, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00803062.
49. Mackay H.J., Tinker A., Winquist E., et al. Aphase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2009, 116:163-167.
50. Monk B.J., Mas Lopez L., Zarba J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. JClin Oncol 2010, 28:3562-3569.
51. Iglehart J.D., Silver D.P. Synthetic lethality: a new direction in cancer-drug development. NEngl J Med 2009, 361:189-191.
52. Hennessy B., Timms K.M., Carey M.S., et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer. JClin Oncol 2010, 28:3570-3576.
53. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA-carriers. NEngl J Med 2009, 361:123-134.
54. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
55. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with high grade serous or poorly differentiated ovarian carcinoma or triple negative breast cancer: a phase 2, multicenter, open-label, non-randomized study. Lancet Oncol 2011, 12:852-861.
56. Kaye SB, Lubinski J, Matulonis U, etal. A phase II, open-label, randomized, multicenter study to compare the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol, in press.
57. Ledermann JA, Harter P, Gourley C, etal. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer [abstract 5003]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting.
58. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010, 16:4527-4531.
59. Bhattacharya R., Kwon J., Ali B., et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008, 14(23):7659-7666.
60. Kaye S, Fehrenbacher L, Holloway R, etal. A phase 2, randomized, placebo-controlled study of hedgehog pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd and 3rd complete remission. Late breaking [abstract 25]. In: Proceedings of the 2010 European Society of Medical Oncology.
61. Elnakat H., Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci 2006, 11:506-519.
62. Ebel W., Routhier E.L., Foley B., et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate recetor-alpha. Cancer Immun 2007, 7:6-13.
63. Armstrong DK, Bicher R, Coleman RL, etal. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum sensitive ovarian cancer in first relapse [abstract 5500]. In: Proceedings of the 2008 American Society of Clinical Oncology meeting.
64. Naumann RW, Coleman RL, Burger RA, etal. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone in subjects with platinum-resistant ovarian cancer [abstract #5045]. In: Proceedings of the 2011 American Society of Clinical Oncology meeting.
65. Miller D.S., Blessing J.A., Krasner C.N., et al. Phase II evaluating pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian cancer or primary peritoneal carcinoma: a Gynecologic Oncology Group study. JClin Oncol 2009, 27:2686-2691.
66. Matulonis U.A., Horowitz N.S., Campos S.M., et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive ovarian cancer. JClin Oncol 2008, 26:5761-5766.
67. Miller D.S., Blessing J.A., Drake R.D., et al. Aphase II evaluation of pemetrexed (Alimta, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2009, 115:443-446.
68. Miller D.S., Blessing J.A., Bodurka D.C., et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008, 110:65-70.
69. Lorusso D., Ferrandina G., Pignata S., et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010, 21(1):61-66.
70. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. NEngl J Med 2008, 358:1160-1174.
71. Grandal M.V., Madshus I.H. Epidermal growth factor receptor and cancer: control of oncogenic signaling by endocytosis. JCell Mol Med 2008, 12:1527-1534.
72. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. JClin Oncol 2005, 23:2445-2459.
73. Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non small cell lung cancer: implications for treatment and tumor biology. JClin Oncol 2005, 23:3227-3234.
74. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non small cell lung cancer patients treated with cetuximab and chemotherapy. JClin Oncol 2008, 26:3351-3357.
75. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
76. Chung C.H., Ely K., McGazvran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. JClin Oncol 2006, 24:4170-4176.
77. Gordon A.N., Finkler N., Edward R.P., et al. Efficacy and safety of eroltinib HCL, and epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor in patients with advanced ovarian cancer: results of a phase II multicenter study. Int J Gynecol Cancer 2005, 15:785-792.
78. Schilder R.J., Sill M.W., Chen X., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian cancer or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005, 11:5539-5548.
79. Posadas E.M., Liel M.S., Kwitkowski V., et al. Aphase II and pharmocodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109:1323-1330.
80. Wagner U., du bois A., Pfisterer J., et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy: a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007, 105:132-137.
81. Bookman M.A., Darcy K.M., Clarke-Pearson D., et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology group. JClin Oncol 2003, 21:283-290.
82. Seiden M.V., Burris H.A., Matulonis U., et al. Aphase II trial of EMD72000 (matuzumab), humanized anti EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007, 104:727-731.
83. Gordon M.S., Matei D., Aghajanian C., et al. Clinical activity of pertuzumab (rhuMAB 2C4), a HER dimerization inhibitor in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. JClin Oncol 2006, 24(26):4324-4332.
84. Secord A.A., Blessing J.A., Armstrong D.K., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group trial. Gynecol Oncol 2008, 108:493-499.
85. Oza A.M., Eisenhauer E.A., Elit L., et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. JClin Oncol 2008, 26:4319-4325.
86. Santin A.D., Sill M.W., McMeekin D.S., et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011, 122:495-500.
87. Farley J., Sill M.W., Birrer M., et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression; a Gynecologic Oncology Group study. Gynecol Oncol 2011, 121:303-308.
88. Schilder R.J., Sill M.W., Lee Y.C., et al. Aphase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2009, 19:929-933.
89. Johnson G.A., Mannel R., Khalifa M., et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol 1997, 65:425-429.
90. Oonk M.H., de Bock G.H., van der Veen D.J., et al. EGFR expression is associated with groin node metastases in vulvar cancer but does not improve their prediction. Gynecol Oncol 2007, 104:109-113.
91. Berchuck A., Rodriguez G., Kamel A., et al. Expression of epidermal growth factor receptor and HER-2/new in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 1990, 76:381-387.
92. Growdon W.B., Boisvert S.L., Akhavanfard S., et al. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008, 111:289-297.
93. Emerling B.M., Akcakanat A. Targeting PI3K/mTOR signaling in cancer. Cancer Res 2011, AACR Meeting Report, [Epub ahead of print].
94. Engelman J.A. Targeting PI3K signaling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer 2009, 9:550-562.
95. Slomovitz B.M., Lu K.H., Johnston T., et al. Target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010, 116:5415-5419.
96. Oza A.M., Elit L., Tsao M.S., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. JClin Oncol 2011, 29:3278-3385.
97. Colombo N, McMeekin S, Schwartz P, etal. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [abstract 5516]. In: Proceedings of the 2007 American Society of Clinical Oncology meeting.
98. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
99. Matulonis U.A., Hirsch M., Palescandolo E., et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 2011, 6(9):e24433.